Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC Priming Followed by Serplulimab and SOX/XELOX for Locally Advanced Gastric Cancer
NCT07621484Phase 2Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Jul 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of serplulimab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Shanghai Changzheng Hospital. Primary endpoint: Pathological Complete Response Rate. Started Jul 2026; status: recruiting.
02
Drugs
serplulimab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07621484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07621484.